Keywords: Daiichi Sankyo, edoxaban, NDA, Japan, VTE, Atrial fibrillation, Xarelto, Bayer

Daiichi Sankyo submits first NDA for oral factor Xa inhibitor, edoxaban, in Japan

Article | 07 April 2010

Print This

Japanese drug major Daiichi Sankyo has submitted a New Drug Application to the domestic Ministry of Health, Labor and Welfare ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in